Article Text

PDF
AB0384 The Effects of Pentoxifylline on Rheumatoid Arthritis Activity According To The DAS28 CRP Disease Activity Score
  1. D.S. Bublikov,
  2. A.V. Andrienko,
  3. V.G. Lychev,
  4. D.A. Anchugina
  1. Department of Hospital Therapy, Altay State Medical University, Barnaul, Russian Federation

Abstract

Background Treatment of rheumatoid arthritis (RA) prior to “Treat to target” is difficult enough, forcing researchers around the world look for ways to improve the effectiveness of RA treatment.

Objectives To explore the possibilities of reducing RA activity on the disease activity score DAS28 CRP by adding pentoxifylline to the methotrexate treatment.

Methods This study included women (n=101) with RA longer than 1 year in duration, have a seropositive rheumatoid factor, and DAS28 CRP activity score of 3.2–5.1. Middle aged – 45.04±5.24 years old. All patients received a 15.50±2.50 mg oral dose of methotrexate per week. Patients were divided into two groups - those who only had methotrexate (n=50) and those who were treated with an oral dose of methotrexate and 1200 mg of pentoxifylline per day (n=51).

Results The baseline for both groups of RA patients did not differ significantly in terms of the level on the DAS28 CRP (p=0.812). On 14th day of the group who were taking pentoxifylline, the DAS28 CRP disease activity score was significantly lower by 12.5% (p<0.001). After 28 days, the users had a DAS28 CRP disease activity score index difference. The difference between two groups is statistically significant. In the group that were treated with pentoxifylline in addition to methotrexate (p=0.001) the index was found to be 8.3% lower. For 28 days, the methotrexate group's disease activity according to the DAS28 CRP activity score significantly decreased by 14.3% from the baseline (p<0.001). For 28 days, the pentoxifylline + methotrexate group also achieved a statistically significant reduction in the index according to the DAS28 CRP activity score by 20.5% (p<0.001)

The disease activity index for the two groups for 14 and 28 days is shown in the table.

DAS28 CRP Index in the two groups of RA patients

Conclusions Thus, converting the monotherapy methotrexate to pentoxifylline will significantly reduce the activity of RA, while avoiding many of the adverse effects of the other combination therapies. This data requires further long-term research.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.